REGENERON PHARMACEUTICALS INC (REGN) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 86% based on the firm’s underlying fundamentals and the ...

A significant trading signal occurred for Regeneron Pharma stock at a price of $501.83, after which REGN rose up to 3.2%.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ...

IQVIA stock may look ready for a breakout, but Adhishthana analysis reveals a complex time spiral that could last until 2030.

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a higher bid. The private-equity firm plans to bid against rival Advent ...

State attorneys general are seeking a ruling in 23andMe’s bankruptcy that the DNA-testing firm needs explicit consent from customers before transferring their genetic data to another company.

Regeneron Pharmaceuticals logged a 4.0% change during today's afternoon session, and is now trading at a price of $513.17 per ...

Tech is back in the driver’s seat, with the sector reigniting the flames across the market indexes (^DJI, ^IXIC, ^GSPC) since their April 8 lows on the rollout of President Trump's "Liberation Day" ...

MAINZ and TÜBINGEN, Germany I June 12, 2025 I BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...